Serum Uric Acid Level Is Positively Associated With Higher Bone Mineral Density at Multiple Skeletal Sites Among Healthy Qataris

Wisam Nabeel Ibrahim1,2, Nadin Younes3, Zumin Shi4 and Marawan Abdelhamid Abu-Madi1,2,3*

1 Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar, 2 Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar, 3 Biomedical Research Center, Qatar University, Doha, Qatar, 4 Department of Human Nutrition, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

Background: Oxidative stress has been implicated as a fundamental mechanism in the decline of bone mass. Although serum uric acid (SUA) has potent antioxidant properties, the findings of many epidemiological and experimental studies couldn’t draw a clear conclusion on the relation between SUA and bone health. We aim to investigate the association between SUA and bone mineral density (BMD) at different skeletal sites among healthy Qataris.

Methodology: A cross-sectional analysis including total-body and site-specific bone mineral density scores and other serological markers of 2981 healthy Qatari adults (36.4 ± 11.1 years) from the Qatar biobank database was conducted. The study participants were divided into quartiles based on the level of SUA, and the BMD was measured using dual-energy X-ray absorptiometry (DXA). Multiple regression analyses were applied to investigate the association between SUA and BMD adjusting for multiple confounding factors.

Results: High levels of SUA were significantly associated with the increased bone mineral density of the total body and at site-specific skeletal locations after adjusting for age and gender (p-value < 0.001). Further adjustment for body mass index (BMI), smoking, vitamin D, alkaline phosphatase, and estimated glomerular filtration rate (eGFR) levels attenuated the association but the association remained significant for individuals with high SUA levels (p-value ≤ 0.01). The association between SUA and BMD was not significant in non-obese, females, young adults, and smokers. However, no interaction was found between SUA and age, gender, BMI and smoking.

Conclusion: Higher SUA levels are associated with a high bone density among healthy Qatari adults. However, such observation demands further investigations to outline the underlying mechanisms.

Keywords: uric acid, bone mineral density, osteoporosis, Qatar biobank, antioxidant, eGFR, BMI, smoking
INTRODUCTION

Disorders of bone mineral density are common risk factors that are ranging from moderate osteopenia to severe osteoporosis (1). Osteoporosis is a chronic systemic disorder in the skeletal system characterized by a pathological reduction in bone density (less than 2.5 standard deviations from normal adults) with compromised bone strength [National Institute of Health, 2001]. Each year, 200 million individuals worldwide are diagnosed with osteoporosis with complicated 9 million fractures (2). Fractures are the most common cause of physical disability and may confer substantial risk for morbidity and mortality among patients with osteoporosis; commonly involving the hip, wrist, or spine bones (3).

The risk factors for having low BMD include smoking, malnutrition, low calcium intake, steroid medications, physical inactivity, alcoholism, and underweight (4). Other non-modifiable risk factors include old age, female gender, and family history of osteoporosis (5).

Generally, the etiology of osteoporosis involves imbalances between the bone-building osteoblasts and the bone-resorbing osteoclasts leading to significant loss of bone matrix components (4). A large body of scientific evidence has confirmed the role of oxidative stress in the age-related decline of bone mass and strength (6). A high level of reactive oxygen species or low level of antioxidants is linked with reduced bone density and osteoporosis (6–9). These antioxidants had demonstrated osteoprotective properties mainly through maintaining the survival and activity of osteoblasts with inhibition of osteoclast cell activity (10).

Serum uric acid (SUA) is the final product of purine nucleosides and free bases degradation in humans and higher primates with potent antioxidant properties (11). However, when present at abnormally high levels it may become a risk factor for many metabolic syndromes and diseases (12–15). SUA is a powerful scavenger of free radicals, which may contribute as an endogenous systemic antioxidant in protecting the bones from deterioration (16). Many experimental and epidemiological studies provided conflicting conclusions about the relation between SUA and bone health (17, 18). Thus, it is hypothesized that SUA is associated with surrogate markers of bone health, leading to speculation about a potential protective role of SUA against bone loss and metabolic bone diseases, such as osteoporosis, owing to its potent antioxidant effects. Therefore, this study was undertaken to retrospectively investigate the correlation of SUA with BMD in a healthy Qatari population.

METHODOLOGY

Ethical Statement

The study was ethically approved by the institutional review board (E-2018-QBB-RES-ACC-0112-0054). All samples used in this study were obtained from Qatar Biobank. Written informed consent has been taken from all participants enrolled in the study.

Subjects

2,981 healthy Qataris aging from 18 to 70 years old volunteered in this study. Samples collection were conducted in Qatar Biobank. A consent from was obtained from all volunteers to use their samples and health information in complete confidentiality by the approved researchers. In addition, all participants signed consent forms agreeing to allow the tracking and assessment of their medical history. The questionnaire information was collected in the interview by a nurse to ensure the accuracy of the patient medical history.

Participants with conditions that might affect bone mass, structure, or metabolism were excluded to minimize their influence on bone mineral density. Patients on corticosteroids treatment for any cause and patients receiving chemotherapy for cancer; chronic disorders involving the vital organs (heart, lung, liver, kidney, brain), history of diabetes, high cholesterol level, high blood pressure, kidney diseases, stroke, arthritis, osteoporosis, fractures, Parkinson disease, thyroid disease, hysterectomy, Hodgkin lymphoma, breast, prostate, and lung cancers were all excluded. The background questionnaire was self-administered and designed to obtain personal socio-demographic data including age, height, weight, and body mass index (BMI). Data regarding the co-morbidities/disease history of the participants and medication or supplement intake were also included in the questionnaire.

Biochemical Investigations

A routine blood biochemistry profile was performed, which included serum uric acid (SUA), calcium, phosphorus, alkaline phosphatase (ALP), serum creatinine, thyroid hormones test, oestrogen, and serum 25-hydroxyvitamin D. The estimated glomerular filtration rate (eGFR) was determined according to the serum creatinine level, and gender following published method of calculation (19).

Dual-Energy X-Ray Absorptiometry (DXA) Scan

The BMD data for all study participants were obtained from Qatar Biobank using Full-body dual-energy iDXA (General Electric, Boston, MA, USA). A trained and certified technician in QBB measured the BMD. The total body BMD in addition to multiple site-specific scans including the lumbar spine (L1-L4), pelvis, trunk, femoral neck, trochanteric, and ward’s triangle were all measured. The DXA scan results were reported as absolute values of BMD (g/cm²). The same DXA machine was used for the screening of all participants and all technicians received training to ensure the reproducibility of the BMD measures.

Statistical Analysis

The statistical analysis was done using Stata 16 (Stata Statistical Software: Release 16. College Station, TX: Stata Corp LLC, USA). Data were expressed as mean values ± SD or frequencies (%). Univariate analysis were completed using One way ANOVA and Chi-square tests as appropriate. The unadjusted relation between total body BMD and SUA level was assessed by Pearson correlation analysis. Multiple regression model analysis was conducted to
evaluate the strength of association between SUA and site-specific BMD after adjustments with different confounding factors. Statistical significance was indicated with p-values less than 0.05.

RESULTS

The Baseline Characteristics According to Serum Uric Acid Quartile Level

The distribution of demographic, biochemical, and bone mass characteristics according to the SUA quartile levels is shown in Table 1. A total of 2,981 Qatari participants were included in the study. The mean age was 36.4 ± 11.1 years. The mean SUA level was 296.53 ± 81.89.

The total body and site-specific BMD including the hip trochanter, trunk, femoral upper neck, ward’s triangle, pelvis, and Lumber spine demonstrated dose dependant response across the quartiles of SUA in the unadjusted analysis. Further, there was a strong association between participants age, BMI, alkaline phosphatase, calcium, oestradiol, eGFR, and the quartile levels of SUA (p<0.01). Each of these variables were positively related with quartiles of SUA level; except for the oestradiol level that had an inverse association with SUA quartiles. A weak association was also evident between SUA quartiles and triiodothyronine level. Dihydroxyvitamin D, smoking, free thyroxin, and phosphorous levels were not associated at all with the quartile levels of SUA as shown in Table 1.

Association Between Serum Uric Acid and Bone Mineral Density

A significant positive correlation was found between SUA and total body BMD as shown in the scatter plot in Figure 1. Figure 2 shows the multiple variable adjusted associations between quartiles of SUA and total body and site-specific BMDs.

Helpful hints:
- The table shows the distribution of baseline characteristics according to serum uric acid quartile levels.
- The results indicate a strong association between SUA and total body BMD, with a dose-dependent response across quartiles.
- Table 1 provides details on sample characteristics and quartile levels of various parameters.

TABLE 1 | Sample characteristics gender-specific quartiles of uric acids among participants attending Qatar Biobank Study (N = 2981).

| Parameter                  | Total   | Q1 N = 759 | Q2 N = 744 | Q3 N = 743 | Q4 N = 735 | p-value |
|----------------------------|---------|------------|------------|------------|------------|---------|
| Age (years)                | 36.4 (11.1) | 34.9 (10.7) | 35.7 (10.7) | 36.3 (11.0) | 38.6 (11.6) | <0.001  |
| Sex (%)                    | 1.00    |            |            |            |            |         |
| Men                        | 1,430 (48.0%) | 362 (47.7%) | 359 (48.3%) | 355 (47.8%) | 354 (48.2%) |         |
| Women                      | 1,551 (52.0%) | 397 (52.3%) | 385 (51.7%) | 388 (52.2%) | 381 (51.8%) |         |
| Smoking (%)                | 0.38    |            |            |            |            |         |
| Non-smoker                 | 2,022 (67.8%) | 491 (64.7%) | 507 (68.1%) | 511 (68.8%) | 513 (69.8%) |         |
| Ex-smoker                  | 186 (6.3%) | 54 (7.1%)  | 52 (7.0%)  | 42 (5.7%)  | 41 (5.6%)  |         |
| Current smoker             | 770 (25.8%) | 214 (28.2%) | 185 (24.9%) | 190 (25.6%) | 181 (24.6%) |         |
| Uric acid (µmol/L)         | 296.53 (81.89) | 222.59 (52.09) | 272.40 (50.16) | 312.00 (54.87) | 381.69 (71.30) | <0.001 |
| BMI (kg/m2)                | 28.4 (5.9) | 25.9 (5.2)  | 27.2 (5.2)  | 29.1 (5.4)  | 31.6 (6.0)  | <0.001  |
| Alkaline phosphatase (U/L) | 68.76 (19.91) | 65.69 (21.45) | 66.42 (17.01) | 71.35 (20.92) | 71.68 (19.21) | <0.001  |
| Calcium (mmol/L)           | 2.28 (0.08) | 2.27 (0.08) | 2.28 (0.07) | 2.28 (0.08) | 2.29 (0.08) | <0.001  |
| Phosphorous (mmol/L)       | 1.15 (0.17) | 1.16 (0.17) | 1.15 (0.16) | 1.15 (0.16) | 1.15 (0.17) | 0.72     |
| Dihydroxyvitamin D (mg/mL) | 18.67 (11.57) | 18.33 (11.69) | 18.31 (10.23) | 18.83 (11.52) | 19.22 (12.73) | 0.38     |
| eGFR (mL/min/1.73m2)       | 111.35 (15.07) | 115.20 (13.79) | 112.45 (14.65) | 111.19 (14.01) | 106.42 (16.41) | <0.001  |
| eGFR< 90 mL/min/1.73m2 (%) | 256 (8.6%) | 40 (5.3%)   | 50 (6.7%)   | 54 (7.3%)   | 112 (15.3%) | <0.001  |
| Estradiol (pmol/L)         | 237.76 (283.47) | 275.70 (326.71) | 252.26 (300.27) | 225.26 (261.94) | 195.93 (226.65) | <0.001  |
| Free Thyroxin (pmol/L)     | 13.18 (1.59) | 13.17 (1.52) | 13.28 (1.71) | 13.12 (1.57) | 13.16 (1.55) | 0.25     |
| Free triiodothyronine (pmol/L) | 4.43 (0.61) | 4.37 (0.57) | 4.46 (0.66) | 4.44 (0.64) | 4.45 (0.56) | 0.022   |
| Thyroid Stimulating Hormone (mIU/L) | 1.61 (1.15) | 1.53 (0.92) | 1.60 (1.18) | 1.70 (1.38) | 1.62 (1.05) | 0.047   |
| Bone mineral density (BMD) score (g/cm²) | 1.21 (0.13) | 1.18 (0.13) | 1.20 (0.13) | 1.21 (0.12) | 1.24 (0.15) | <0.001  |
| Total body                 | 0.82 (0.14) | 0.79 (0.14) | 0.81 (0.14) | 0.83 (0.13) | 0.86 (0.14) | <0.001  |
| Hip trochanter             | 1.00 (0.12) | 0.98 (0.12) | 1.00 (0.12) | 1.01 (0.11) | 1.03 (0.12) | <0.001  |
| Femoral upper neck         | 0.85 (0.16) | 0.83 (0.16) | 0.84 (0.16) | 0.85 (0.16) | 0.87 (0.17) | <0.001  |
| Ward’s triangle            | 0.83 (0.16) | 0.81 (0.16) | 0.83 (0.16) | 0.84 (0.16) | 0.86 (0.17) | <0.001  |
| Pelvis                     | 1.01 (0.13) | 0.99 (0.14) | 1.00 (0.13) | 1.01 (0.12) | 1.04 (0.14) | <0.001  |
| Lumber spine               | 1.11 (0.14) | 1.08 (0.15) | 1.11 (0.14) | 1.12 (0.13) | 1.15 (0.14) | <0.001  |

Data are presented as mean (SD) for continuous measures, and n (%) for categorical measures.
FIGURE 2 | Multiple regression analysis of the association between quartiles of serum uric acid (µmol/L) and bone mineral density (BMD) for total body and multiple skeletal locations (g/cm²). Values represent the regression coefficients per SD change of uric acid. Model 1 adjusted for age and gender. Model 2 adjusted for age, gender, BMI, serum vitamin D, Alkaline Phosphatase, eGFR, and smoking status.
The first model demonstrated a significant dose-response relationship between serum uric acid and all BMD scores (total body and all site-specific) after adjustment for age and gender. Across quartiles of SUA from low to high, total body and all site-specific BMDs increased. In the second model of adjustments for confounders including age, gender, BMI, serum vitamin D, Alkaline Phosphatase, estimate glomerular filtration rate (eGFR), and smoking status, the above associations were attenuated. However, compared with the first quartile of SUA, the highest quartile had a significantly higher BMD including total body BMD and all site-specific BMDs except for lumbar spine BMD.

The subgroup analysis stratified by age, sex, BMI, and smoking status confirmed the overall positive association between SUA, and total body BMD (Figure 3). Although the association between SUA and total body BMD was not statistically significant in young adults, women, non-obese, and smokers, no significant interactions between SUA and sex, age, BMI, and smoking were found.

**DISCUSSION**

Low BMD is a pathological condition often asymptomatic progressing over years to more serious bone complications like osteoporosis and pathological fractures without any clinical clue (20). Many epidemiological and experimental studies provided inconsistent conclusions about the relation between SUA and BMD. Therefore, this study aimed to investigate the relation between SUA and bone health among healthy Qatari individuals.

The BMD score was used in this study as a measure of bone health by measuring mineral density using dual-energy x-ray absorptiometry (DXA). This technique is considered globally as the standard tool in estimating bone health due to its accuracy and cost-effectiveness. The assessment of other bone components like collagenous and non-collagenous proteins that contribute significantly to bone health is however of limited use (21). Different skeletal anatomical locations were selected in the DXA scan to increase the reliability of the measurements including the total body, hip trochanters, trunk, femoral upper neck, ward’s triangle, pelvis, and lumbar spine BMDs.

The level of SUA was assessed together with BMD and other serological parameters in a relatively large population sample, representative of the healthy Qatari population. A positive association was evident between the quartiles of SUA level and the BMD scores as shown in Table 1. As shown in the table, subjects with higher SUA levels had significantly higher BMD at different skeletal sites (p<0.001). The baseline correlation analysis of total body BMD confirmed a significant positive association with SUA level.

Further investigation of multiple variable adjusted associations between quartiles of SUA, total body BMD, and site-specific BMDs confirmed the significant positive association between the quartiles of SUA and all site-specific BMDs in a dose-response pattern after adjustment for age and gender. Age

---

**FIGURE 3** | Subgroup analysis of the association between uric acid and total body BMD stratified by age, sex, obesity, and smoking status. Values represent the regression coefficients per SD change of uric acid. Models adjusted for age, gender, BMI, serum vitamin D, alkaline phosphatase, eGFR, and smoking status. Stratification variables were not adjusted in corresponding models.
and gender contribute significantly to the BMD as elderly people and post-menopausal women, in particular, who are at higher risks for developing osteoporosis in part, due to increased bone resorption rates and the declining estrogen levels (22).

Further adjustments for age, gender, BMI, serum vitamin D, alkaline phosphatase, and smoking status confirmed high-level of SUA was positively associated with BMD in all skeletal sites except the lumbar spine. Although, the association and the dose-response effect were attenuated after the adjustment indicating the possible confounding factors. This may indicate BMI, age are independent factors significantly contributing to BMD. Similarly in another cross-sectional study, BMI and adiposity were independently associated with BMD as they attenuated the association between SUA and BMD to marginal significance after adjustment (23). Such finding was also confirmed in other studies (24, 25). In the study conducted by Han et al. on a group of Chinese postmenopausal women, SUA was significantly associated with lumbar BMD after adjustments for the aforementioned factors in addition to blood pressure, alcohol intake, milk intake, and calcium supplements (26).

The subgroup analysis of the adjusted regression model indicated no significant interaction between SUA and sex, age, BMI, and smoking. The study also confirmed no significant association between SUA and total body BMD in young adults, women, non-obese, and smokers. This finding is supported by several epidemiological studies using different study designs and population samples (23, 24, 26–40) as listed in Table 2. These epidemiological studies aimed to elucidate the relation between SUA and bone health. Many cross-sectional studies have confirmed the positive association between SUA and BMD in both genders and all age groups after adjustment for potential confounders (28, 36, 38). In other cross-sectional studies, the positive association was dependant on a significant interaction of SUA level with age and vitamin C level (40), central adiposity, or obesity among postmenopausal women (23, 24, 26). Other cross-sectional studies have suggested an additional protective effect of SUA against the development of osteoporosis or osteoporotic fractures (27, 30, 32, 33, 37, 39).

Consistently two longitudinal studies had concluded the positive association between SUA and annual rates of change in BMD at different skeletal sites (31) and lower risk in developing osteoporotic fractures (29). Interestingly, other studies had additionally confirmed the lack of association between SUA and BMD in young females (35) and black Americans (34).

In contrast to these observations, a group of epidemiological studies confirmed no association between SUA and BMD after adjusting confounders in the multiple regression analysis (41). One cross-sectional study in the USA also confirmed no association between SUA and the risk of non-vertebral fractures among gout patients (42). Another cross-sectional study in Italy even concluded higher risks of hip fractures among men with high SUA levels due to the role of inflammatory factors and the involvement of oxidative stress response (43). However, the risk of fracture is not only determined by BMD; besides, physical activity, smoking, nutrition, weight loss, and several hormonal and therapeutic agents might count. In one longitudinal study in Italy despite the baseline relation of high SUA with lower risk with osteoporosis; however, the association was not evident with the follow-up of the participants up to 4 years (44). These conflicting observations may be attributed to the demographic characteristics, confounding factors being controlled, population sample, study designs, and other limitations.

Interestingly, one Mendelian randomization study found no causal effect of SUA or gout with BMD (45). However, randomized Mendelian studies carry many limitations because the level of SUA is not merely determined by genetic factors. Instead, several environmental factors may obviate the genetic influence such as daily intake of purine diet, alcoholism, diuretics, high blood pressure, and high blood sugar (46). Other limitations of randomized Mendelian studies may include multiple biological effects of the genetic variant (pleiotropy) that may independently affect SUA level in

| Study | Country | Skeletal site of Bone scan | Sample Size | Participants Type |
|-------|---------|----------------------------|-------------|-------------------|
| Ahn et al. (27) | Korea | lumbar spine, femoral neck, total hip, and trochanter | 7502 | Postmenopausal women |
| Ishii et al. (28) | Japan | Lumbar spine | 615 | Peri & Postmenopausal women |
| Kim et al. (29) | Korea | Osteoporotic fractures | 16078 | Men aged over 50 years |
| Lane et al. (30) | USA | Total hip | 1680 | Men aged over 65 years |
| Makovey et al. (31) | Australia | Femoral neck, hip, lumbar spine, total body | 356 | Peri & Postmenopausal women |
| Nabipour et al. (32) | Australia | Lumbar spine and right hip | 1705 | Men aged over 70 years |
| Babaei et al. (33) | Iran | Lumbar spine and femoral neck | 1080 | Men and women aged over 70 years |
| Karimi et al. (34) | Iran | Total body, lumbar spine, and left femoral neck | 413 | Healthy young adults |
| Alosami et al. (35) | Iraq | Lumbar spine and right femoral neck | 151 | Postmenopausal women |
| Han et al. (36) | China | Lumbar spine | 390 | Postmenopausal women |
| Yao et al. (37) | USA | Lumbar spine | 4156 | Old adults aged over 60 years |
| Pan et al. (38) | USA | Total body | 7320 | Healthy young adults |
| Bonaccorsi et al. (24) | Italy | Hip | 358 | Pre & Postmenopausal women |
| Pirro et al. (39) | Italy | Femur | 180 | Postmenopausal osteoporotic women |
| Muka et al. (40) | Netherlands | Femurul neck and hip bone geometry | 5074 | Population study (Rotterdam Study) |
| Chen et al. (41) | China | Lumbar spine and left femoral neck | 253 | Primary osteoporosis patients |
| Kaushal et al. (42) | India | Femur neck, total femur, and lumbar spine | 524 | Healthy adults |
addition to the consequences of linkage disequilibrium that involve other confounding genetic variants.

The hypothesized mechanism played by SUA in promoting bone health is attributed to its antioxidant properties. Accumulating evidence suggests the plausible involvement of oxidative stress as a fundamental contributor to age-related bone loss. Oxidative stress inhibits osteoblast cell differentiation and function in mineralizing the bone tissue and may even induce cell death with evident reversal of all changes upon treatment with antioxidants such as Trolox or ascorbic acid (47, 48). Oxidative stress may also stimulate the development and function of osteoclast cells that exhibit bone resorption via ROS-mediated mechanisms (49, 50).

Several studies have shown that SUA is a strong endogenous antioxidant that counts nearly for half of the plasma’s antioxidant potential (51). Hence, SUA may promote proliferation and osteogenic differentiation and protect against metabolic bone diseases, such as osteoporosis. This observation was confirmed in human bone mesenchymal stem cells in vitro. Interestingly uric acid enhances the proliferation and differentiation of the cells, increases deposition of calcium crystals, and inhibits the adipogenic stem cells of the bone (52). Moreover, uric acid inhibits the formation and function of osteoclast cells in vitro with a dose-dependent effect through interference with ROS precursors within the osteoclast cells (27). However, unfavorable effects are elicited with very high levels of uric acid in vitro and in vivo gout models. At such levels, uric acid is found to inhibit the proliferation and differentiation of osteoblast cells and the toxic effects were reversed upon treatment with anti-hyperuricemia agents like allopurinol (53).

One experimental study confirmed no difference in the BMD and bone biochemical parameters among rat models of hyperuricemia compared to the control rats (41). This observation could be attributed to other confounding antioxidants such as ascorbic acid. Interestingly, unlike in humans, ascorbic acid can be biosynthesized in rodents due to the lack of gluconolactone oxidase enzyme in human beings (54). Like SUA, ascorbic acid is a powerful antioxidant and may confer osteoprotective properties despite low or normal levels of SUA. Thus, SUA can effectively prevent the production of ROS in human osteoblasts and stimulate its differentiation, hence, increasing bone formation and optimize bone health when present at normal levels.

Another finding in this study is the low level of vitamin D among the healthy participants as shown in Table 1. Despite the abundant sunshine in the Middle East and Asia compared to Europe and the United States, countries in these areas have reported the highest rate of hypovitaminosis D worldwide. For instance, in Thailand, the prevalence of vitamin D deficiency was found to be in 77% of pre-menopausal women, and it reached up to 90% in India (55, 56). Qatari population has one of the highest prevalence rates of vitamin D insufficiency that is approximately affecting 90.4% of the population (57). Low intake of vitamin D supplements may contribute to the deficiency status among the younger population. Hence, the estimation of vitamin D deficiency/insufficiency becomes mandatory before reporting bone status in young as well as post-menopausal women.

The limitation of this study is attributed to the cross-sectional design where it is difficult to determine a causal relationship between BMD and SUA. Longitudinal studies are necessary to elucidate this relation though it was confirmed in other populations. In addition, many subjects were excluded from the analysis such as patients on corticosteroids treatment and patients receiving chemotherapy for cancer because both conditions may significantly interfere with BMD (57); similarly, multiple pieces of evidence confirmed the relationship between low BMD and chronic disorders involving the vital organs (heart, lung, liver, kidney, brain), diabetes, high cholesterol level, high blood pressure, kidney diseases, stroke, arthritis, osteoporosis, fractures, Parkinson disease, thyroid disease, hysterectomy, Hodgkin lymphoma, breast, prostate, and lung cancers. Therefore, the findings in this study may not apply to individuals with above conditions. The study mandates more experimental studies in vitro and in vivo controlling confounding factors such as ascorbic acid and other antioxidants to unravel the underpinning mechanisms and pave the way for future therapeutic approaches.

**CONCLUSION**

The study concluded the possible osteoprotective properties of SUA among healthy Qatari adults. The observed association was not confirmed in non obese, females, young adults and smokers. The healthy Qatari population had also significantly low levels of vitamin D. Further efforts are required to investigate the plausible molecular mechanisms of the effects involving uric acid in bone metabolism and to correct the evident state of vitamin D deficiency in Qatar.

**DATA AVAILABILITY STATEMENT**

Restrictions apply to the availability of these data. Data was obtained from Qatar Biobank (https://www.qatarbiobank.org.qa/) and are available from Qatar Biobank upon request.

**ETHICS STATEMENT**

The study involved human participants and was reviewed and approved by Institutional review board (IRB) at Qatar university (E-2018-QBB-RES-ACC-0112-0054). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

WI conceptualized the topic, wrote and edited the manuscript, contributed in data curation and the statistical analysis. NY completed the statistical analysis, reviewed the manuscript. MA-M project administration, supervision, and reviewing the manuscript. All authors contributed to the article and approved the submitted version.
ACKNOWLEDGMENTS

The authors would like to acknowledge the contribution of Qatar biobank in this study.

REFERENCES

1. Karaguzel G, Holick MF. Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord (2010) 11(4):237–51. doi: 10.1007/s11154-010-9154-0

2. Sözen T, Ozyüz B, Başaran Ç. An overview and management of osteoporosis. Eur J Rheumatol (2017) 4(1):46–56. doi: 10.5152/ eurheum.2016.048

3. Tatangelo G, Watts J, Lim K, Connaughton C, Abinunyi-Öchom J, Borgström F, et al. The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. J Bone Miner Res (2019) 34(4):616–25. doi: 10.1002/jbmr.3640

4. Borba-Pinheiro C, Carvalho M, Dantas E. Osteopenia: a silent warning to women of the XXI century. Rev Educ Fis (2008) 140:43–51. doi: 10.1177/ 1759720X11401674

5. Sánchez-Riera I, Carnahan E, Vos T, Veerman L, Norman R, Lim SS, et al. The global burden attributable to low bone mineral density. Ann Rheum Dis (2014) 73(9):1635–45. doi: 10.1136/annrheumdis-2013-204520

6. Domazetovic V, Marchetti G, Iamonti T, Brandi ML, Vincenzi MT. Oxidative stress in bone remodeling: role of antioxidants. Clin Cases Miner Bone Metab (2017) 14(2):209–16. doi: 10.11138/ccmb.2017.14.2.209

7. Agidigbi TS, Kim C. Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases. Int J Mol Sci (2019) 20(14):3576. doi: 10.3390/ijms20143576

8. Wang T, Liu Q, Jhioe W, Zhao J, Lu A, Zhang G, et al. Therapeutic Potential and Possible Factors in Multifactorial Disorders of Osteoporosis in Women: A Comparative Study from the Western Region of Nepal. J Clin Diagn Res (2012) 6:274–7.

9. Vondracek SF, Linnebur SA. Diagnosis and management of osteoporosis in the older senior. Clin Interventions Aging (2009) 4:1211–36. doi: 10.2147/ CIA.S4965

10. Pirro M, Mannarino MR, Bianconi V, De Vuono S, Sahebkar A, Bagaglia F, et al. Uric acid and bone mineral density in postmenopausal osteoporotic women: the link lies within the fat. Osteoporos Int (2017) 28(3):973–81. doi: 10.1007/s00198-016-3792-3

11. Bonacorsi G, Trentini A, Greco P, Tisato V, Gemmatti D, Bianchi N, et al. Changes in Adipose Tissue Distribution and Association between Uric Acid and Bone Health during Menopause Transition. Int J Mol Sci (2019) 20(24):6321. doi: 10.3390/ijms20246321

12. Niu S, Lim F: CE: The Effects of Smoking on Bone Health and Healing. Am J Nurs (2020) 120(7):40–5. doi: 10.1097/01.NAJ.0000681644.64148.e

13. Han W, Bai X, Wang N, Han L, Sun X, Chen X. Association between lumbar bone mineral density and serum uric acid in postmenopausal women: a cross-sectional study of healthy Chinese population. Arch Osteoporos (2017) 12(1):50. doi: 10.1186/s11657-017-0345-0

14. Ahn SH, Lee SH, Kim BJ, Lim KH, Bae SJ, Kim EH, et al. Higher serum uric acid is associated with higher bone mass, lower bone turnover, and lower prevalence of vertebral fracture in healthy postmenopausal women. Osteoporos Int (2013) 24(12):2961–70. doi: 10.1007/s00198-013-2377-7

15. Ishii S, Miyao M, Mizuno Y, Tanaka-Ishikawa M, Akishita M, Ouchi Y. Association between serum uric acid and lumbar spine bone mineral density in peri- and postmenopausal Japanese women. Osteoporos Int (2014) 25(3):1099–105. doi: 10.1007/s00198-013-2571-7

16. Kim BJ, Baek S, Ahn SH, Kim SH, Jo MW, Bae SJ, et al. Higher serum uric acid as a protective factor against incident osteoporotic fractures in Korean men: a longitudinal study using the National Claim Registry. Osteoporos Int (2014) 25(7):1387–44. doi: 10.1007/s00198-014-2697-2

17. Lane NE, Parimi N, Lui LY, Wise BL, Yao W, Lay YA, et al. Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoprotective Fractures in Men (MrOS) study. J Bone Miner Res (2014) 29(7):1701–7. doi: 10.1002/jbmr.2164

18. Makovej J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ, et al. Serum uric acid plays a protective role for bone loss in peri- and postmenopausal women: a longitudinal study. Bone (2013) 52(1):400–6. doi: 10.1016/ j.bone.2012.10.025

19. Nabipour J, Sambrook PN, Blyth FM, Janu MR, Waite LM, Naganathan V, et al. Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res (2011) 26(5):955–64. doi: 10.1002/jbmr.286

20. Babaei M, Shamsi R, Heidari B, Bijani A, Hosseini SR. Serum Uric Acid Status and Its Association with Bone Mineral Density in the Elderly People Aged 60 Years and More. Int J Endocrinol (2019) 17(3):e80780. doi: 10.5812/ ijem.80780

21. Yao X, Chen L, Xu H, Zhu Z. The Association between Serum Uric Acid and Bone Mineral Density in Older Adults. Int J Endocrinol (2020) 2020:3082318. doi: 10.1155/2020/3082318

22. Pan K, Yao X, Liu M, Zhu Z. Association of Serum Uric Acid Status With Bone Mineral Density in Adolescents Aged 12–19 Years. Front Med (Lauanne) (2020) 7:255. doi: 10.3389/fmed.2020.00255

FUNDING

This study was funded by Qatar University, grant # QUST-1-CHS-2019-16.

Ibrahim et al. Osteoprotective Potentials of Serum Uric Acid

Frontiers in Endocrinology | www.frontiersin.org 8 March 2021 | Volume 12 | Article 653685
47. Bai XC, Dabbaghmanesh MH, Omrani GR. Association between serum uric acid and bone health in adolescents. *Osteoporos Int* (2019) 30(10):2057–64. doi: 10.1007/s00198-019-04072-w

46. Chen L, Peng Y, Fang F, Chen J, Pan L, You L. Correlation of serum uric acid with bone mineral density and fragility fracture in patients with primary osteoporosis: a single-center retrospective study of 253 cases. *Int J Clin Exp Med* (2015) 8(4):6291–4.

45. Kaushal N, Vohora D, Jalali RK, Jha S. Raised serum uric acid is associated with higher bone mineral density in a cross-sectional study of a healthy Indian population. *Ther Clin Risk Manage* (2018) 14:75–82. doi: 10.2147/TCRM.S147696

44. Alosami MH, Adnan S, Hameed EK. Serum uric acid level and bone mineral density in Iraqi postmenopausal women. *Egyptian Rheumatol* (2015) 41(3):221–4. doi: 10.1016/j.jrrh.2018.07.009

43. Kim SC, Paik JM, Liu J, Curhan GC, Solomon DH. Gout and the Risk of Non-insulin-Dependent Diabetes Mellitus. *Eur J Clin Invest* (1997) 27(6):484–90. doi: 10.1111/j.1365-2362.1997.1390687.x

42. Mehta T, Bhandari M, Sharma V, et al. Association between serum uric acid and incident osteoporotic fractures in old people: The PRO.V.A study. *Bone* (2015) 79:183–9. doi: 10.1016/j.bone.2015.06.005

41. Lee YH, Song GG. Uric acid level, gout and bone mineral density: A Mendelian randomization study. *Eur J Clin Invest* (2019) 49(9):e13156. doi: 10.1111/eci.13156

40. Veronese N, Bolzetta F, De Rui M, Maggi S, Noale M, Zambon S, et al. Serum uric acid and incident osteoporotic fractures in old people: The PRO.V.A study. *Bone* (2015) 79:183–9. doi: 10.1016/j.bone.2015.06.005

39. Nishikimi M, Yagi K. Molecular basis for the deactivation of xanthine oxidase. *J Biochem Mol Toxicol* (2015) 29(8):382–7. doi: 10.1002/jbt.21707

38. Li HZ, Chen Z, Hou CL, Tang YK, Wang F, Fu GQ. Uric Acid Promotes Osteogenic Differentiation and Inhibits Adipogenic Differentiation of Human Bone Mesenchymal Stem Cells. *J Biochem Mol Toxicol* (2015) 29(8):382–7. doi: 10.1002/jbt.21707

37. Chen L, Peng Y, Fang F, Chen J, Pan L, You L. Correlation of serum uric acid and bone mineral density in the general population and in rats with experimental hyperuricemia. *J Bone Miner Res* (2015) 30(6):992–9. doi: 10.1002/jbmr.2430

36. Lee YH, Song GG. Uric acid level, gout and bone mineral density: A Mendelian randomization study. *Eur J Clin Invest* (2019) 49(9):e13156. doi: 10.1111/eci.13156

35. Mody N, Parhami F, Saraian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. *Free Radic Biol Med* (2001) 31(4):509–19. doi: 10.1016/S0891-5849(01)00610-4

34. Kim LM, Lu CL, Hung KC, Wu PC, Pan CF, Wu CJ, et al. The Paradoxical Role of Uric Acid in Osteoporosis. *Nutrients* (2019) 11(9):2111. doi: 10.3390/nu1109211

33. Fraser JH, Helfrich MH, Wallace HM, Ralston SH. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. *Bone* (1996) 19(3):223–6. doi: 10.1016/8756-3282(96)00177-9

32. Mehta T, Bhandari M, Sharma V, et al. Association between serum uric acid and incident osteoporotic fractures in old people: The PRO.V.A study. *Bone* (2015) 79:183–9. doi: 10.1016/j.bone.2015.06.005